Health Care [ 6/12 ] | Biotechnology [ 27/74 ]
NYSE | Common Stock
Biohaven Ltd. discovers, develops, and commercializes therapies for immunology, neuroscience, and oncology worldwide.
The company develops troriluzole, which is in Phase 3 trial for the treatment of neurological and neuropsychiatric illnesses; taldefgrobep alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 3 clinical trial for the treatment of focal and generalized epilepsy, and major depressive disorder; BHV-2100 that is in Phase 2 clinical trial for the treatment of migraines and pain disorders; BHV-1510, which is in Phase ½ trial that targets advanced or metastatic epithelial tumors; and BHV-8000, a product candidate that completed Phase 1 clinical trial for the treatment of Alzheimer's and Parkinson's disease, and multiple sclerosis, as well as prevention of amyloid-related imaging abnormalities.
It is also developing BHV-1300, which in Phase 1 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 1 trial for IgA nephropathy; BHV-1100, which is in Phase 1 trial for multiple myeloma patients; BHV-1600, which is in Phase 1 trial for the treatment of peripartum cardiomyopathy; BHV-1310 that is in preclinical trial for the treatment of generalized myasthenia gravis and other acute exacerbations or flares; BHV-1530, which is in preclinical trial to treat urothelial cancer; BHV-1500 that is in preclinical trial for Hodgkin's lymphoma; and BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors.
The company has strategic partnerships with MerusN. V., GeneQuantum Healthcare (Suzhou) Co. Ltd., Aimed Bio, Inc., Yale University, Katholieke Universiteit Leuven, Bristol Meyers Squibb, and Hangzhou Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022.
Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 3, 25 | -1.71 Increased by +5.52% | -1.47 Decreased by -16.23% |
| Nov 13, 24 | -1.74 Decreased by -16.00% | -1.55 Decreased by -12.21% |
| Aug 9, 24 | -3.50 Decreased by -165.15% | -1.70 Decreased by -106.15% |
| May 9, 24 | -2.20 Decreased by -113.59% | -1.57 Decreased by -40.13% |
| Feb 29, 24 | -1.81 Increased by +45.48% | -1.41 Decreased by -28.37% |
| Nov 14, 23 | -1.50 Increased by +14.29% | -1.34 Decreased by -11.94% |
| Jul 31, 23 | -1.32 Increased by +78.74% | -1.21 Decreased by -9.09% |
| May 12, 23 | -1.03 Increased by +65.32% | -1.41 Increased by +26.95% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 0.00 Decreased by N/A% | -186.84 M Decreased by -29.07% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -160.30 M Decreased by -56.28% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -319.77 M Decreased by -253.94% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -179.50 M Decreased by -154.64% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Increased by +100.00% | -144.76 M Increased by +28.02% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -102.57 M Decreased by -48.98% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by -100.00% | -90.35 M Increased by +55.56% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by -100.00% | -70.49 M Increased by +27.35% | Decreased by N/A% Decreased by N/A% |